Cytogenetic and molecular abnormalities such as FLT3 and NPM-1 were identified in cfDNA, suggesting a feasible role for cfDNA in predicting AML prognosis and treatment indications (4). The gene discussed is NPM1; the disease is acute myeloid leukemia.